National Assembly Report Highlights "Issues and Tasks of Allowing Mifegyne"


Debates Whether Legal Amendments Should Precede Product Approval


Divided Opinions on Mandatory Counseling and Prescription/Administration Methods

With the government recently formalizing the official introduction of Mifegyne, discussions over the abortion system have been reignited. This move also signals the end of the seven-year legislative vacuum that followed the Constitutional Court's 2019 decision declaring the abortion ban unconstitutional. Expectations are high that this will lead to a complete overhaul of the legal and medical standards governing abortion, going far beyond the simple introduction of a new medication.


After President Lee Jaemyung instructed a review of Mifegyne’s introduction during a cabinet meeting this past July, the Ministry of Health and Welfare, the Ministry of Gender Equality and Family, and the Ministry of Food and Drug Safety began consultations. The government then announced that it would proceed with the product approval procedures. However, key issues such as the scope of approval for Mifegyne, who may prescribe it, how it may be administered, and oversight systems remain sharply divided.

Won Minkyoung, Minister of Gender Equality and Family, is making an announcement on the official introduction plan of abortion medication at the Government Complex Seoul in Jongno-gu, Seoul, on the 16th. 2026.9.16 Photo by Yojongjun

Won Minkyoung, Minister of Gender Equality and Family, is making an announcement on the official introduction plan of abortion medication at the Government Complex Seoul in Jongno-gu, Seoul, on the 16th. 2026.9.16 Photo by Yojongjun

View original image

A report titled "The Issues and Tasks of Allowing Mifegyne" published by the National Assembly Research Service on September 18 reviewed the controversies surrounding the approval of Mifegyne, the need to reorganize the abortion system, and presented concrete legislative policy tasks.


First, there are conflicting legal interpretations as to whether the Ministry of Food and Drug Safety can proceed with product approval without amending relevant laws such as the Pharmaceutical Affairs Act, the Criminal Act, or the Mother and Child Health Act. Some in the medical and legal community argue that the scope of permitted abortions involves adjustments to fundamental rights and therefore cannot be decided solely by the executive branch. On the other hand, opponents contend that: ▲ The relevant provisions banning abortion in the Criminal Act have already lost their effect; ▲ There are no explicit regulations in the Pharmaceutical Affairs Act prohibiting product approval of abortion medication; and ▲ The Ministry of Food and Drug Safety can grant product approval after reviewing safety, efficacy, and quality, even before the Criminal Act and Mother and Child Health Act are amended.


The method of prescription and administration is also a hotly debated topic. The medical community stresses the importance of safety measures such as ultrasound diagnostics, confirmation of ectopic pregnancy, and an established emergency medical system—insisting that medications should be administered within medical institutions as a rule. However, there are also arguments, citing international standards set by the World Health Organization (WHO), that under certain conditions, at-home use and self-management should be acknowledged.


Safety concerns regarding Mifegyne reflect the tension between international evidence and the level of readiness in the domestic medical system. While the WHO recognizes medication abortion as a safe method, the Ministry of Health and Welfare and the Ministry of Food and Drug Safety are taking a cautious approach. The two ministries have stated, "We are not refusing approval on the grounds that the safety of Mifegyne has not been proven. However, in order to properly review safety, efficacy, and risk management plans as a pharmaceutical product, the scope of permitted abortions and conditions of use must be clearly defined."


The Ministry of Health and Welfare largely maintains the position that the legal standards for the abortion system as a whole must be reorganized first. In other words, introducing Mifegyne involves various aspects of the healthcare system—such as who has prescribing rights, counseling procedures, standards for medical institutions, and health insurance coverage—and cannot be resolved simply with product approval from the Ministry of Food and Drug Safety.

Key Issues in Introducing Mifegyne: "Administration in Medical Institutions" vs "No Restriction on Self-Determination" View original image

There is also debate over whether the legally permitted gestational period for abortion should coincide with the period during which medication can be used. The Ministry of Food and Drug Safety has insisted that legal adjustments should precede the determination of the permitted weeks of use for the medication. However, the Ministry of Government Legislation has separated the issues, stating, "The gestational age for medication use and the legally permitted gestational age for abortion are different matters." It has held the position that product approval cannot be restricted solely because laws regarding the permitted gestational age have not been established, proposing abortion legislation as a subsequent legislative task.


Opinions are also divided on whether counseling and a mandatory waiting period should be required. While some claim that sufficient information must be provided as it is an important decision, women's groups argue that it restricts women's right to self-determination, may delay the gestational age at time of abortion, and could impose an excessive burden on women who are victims of sexual violence or who live in areas with limited access to medical institutions.


Younjung Jeon, Legislative Investigator at the National Assembly Research Service, stated, "Instead of setting the product approval of Mifegyne and legal amendments as a question of which comes first, there needs to be consideration for advancing both simultaneously. Matters such as the period, reasons, and procedures for permitting abortion should be institutionalized as the relevant laws are revised."



She emphasized, "The National Assembly should first determine the direction of legal revisions through public debate and deliberation, and urgently pursue amendments to the Criminal Act and the Mother and Child Health Act to fill the legislative gap in the abortion system."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing